

5367.230-US  
October 27, 2004

Application Number 10/730,215  
Page 10 of 10


### REMARKS

The present amendments are designed to bring the application into compliance with the sequence rules, particularly as set forth in WIPO Standard ST.25. In this respect, the reference "X9" in the formula used to described various claimed/described polypeptides (see, e.g., original claim 1), used to represent 0-2 amino acid residues, is hereby replaced with the references Xaa<sup>9</sup> and Xaa<sup>10</sup> in the amended formulas and SEQ ID NO:1 (each of which references may represent a maximum of one amino acid residue). In a related sense, the reference "X1" in the originally presented formula has been removed from the amended formula and SEQ ID NO:1 as this reference potentially represented no residue, a sequence of several residues, or a fragment of such a sequence. The other amendments are provided to correct obvious typographical errors (misnumbering of "aspects", use of the term GLP-1 instead of GLP-2, etc.). No new matter has been added by way of these amendments.

It is respectfully submitted that the elected claims are in condition for allowance. Early action to that end is respectfully requested. The Commissioner is hereby authorized to charge any fees in connection with this application and to credit any overpayments to Deposit Account No. 14-1447. If, in the opinion of the Examiner, a telephone conference would expedite the prosecution and allowance of this application, the Examiner is hereby invited to call the undersigned attorney.

Respectfully submitted,

Date: October 27, 2004



Len S. Smith, Reg. No. 43,139  
Novo Nordisk Pharmaceuticals, Inc.  
100 College Road West  
Princeton, NJ 08540  
(609) 987-5800